Summary
This filing is an amendment to a previous 8-K report, specifically addressing an agreement between Vertex Pharmaceuticals Incorporated (VRTX) and Mitsubishi Pharma Corporation. The amendment is primarily to refile the License, Development and Commercialization Agreement with revised redactions based on the SEC's review of Vertex's confidential treatment request. For investors, this means the details of the agreement, previously redacted, are now presented with updated confidential information removed. While the core terms of the partnership with Mitsubishi are now more accessible, the specific financial or strategic details that Vertex deemed confidential remain protected. Investors should review the updated Exhibit 99.2 to understand the revised level of disclosure regarding this important collaboration.
Key Highlights
- 1Amendment to a previous Form 8-K filing by Vertex Pharmaceuticals Incorporated.
- 2The amendment relates to the License, Development and Commercialization Agreement with Mitsubishi Pharma Corporation, dated June 11, 2004.
- 3The purpose of the amendment is to refile the agreement with revised redactions after SEC review of a confidential treatment request.
- 4Exhibit 99.2 now contains the agreement with updated confidential information redacted.
- 5The event date reported is June 11, 2004, the effective date of the agreement.
- 6The filing was made on September 9, 2004, with the earliest event date being June 11, 2004.